Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
12,091 GBX | -0.62% | -2.20% | +14.13% |
May. 16 | AstraZeneca's Sipavibart Prevents COVID-19 in Immunocompromised Patients in Phase 3 Trial | MT |
May. 16 | Global markets live: Cisco, EasyJet, Roche, Netflix, Amazon... |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+14.13% | 239B | |
+32.59% | 694B | |
+29.25% | 593B | |
-1.54% | 371B | |
+19.75% | 331B | |
+6.58% | 290B | |
-2.99% | 209B | |
+9.97% | 209B | |
+8.08% | 169B | |
-0.64% | 164B |
- Stock Market
- Equities
- AZN Stock
- News AstraZeneca PLC
- AstraZeneca Gets Indian Drug Regulator's Nod to Import Andexanet Alfa Powder for Solution for Infusion